Innovative decentralized trial aims to increase patient participation and accelerate research for one of the deadliest, under-researched lung cancers SAN CARLOS, CA – June 12, 2025 — GO2 for Lung Cancer (GO2) and the Addario Lung Cancer Medical Institute [...]
Matthew Reiss MSE PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer, and Jared Weiss MD, Section Chief of Thoracic and Head & Neck Oncology, Professor of Medicine, University of North Carolina at Chapel Hill It is [...]
On September 12, 2024, the U.S. Food and Drug Administration (FDA) announced its approval of Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) for subcutaneous injection, commonly known as a shot. This approval included all the same uses of Tecentriq (atezolizumab) that [...]
By Renee Botello MSc, Navigator, Treatment and Trials, GO2 for Lung Cancer and Roy Herbst, MD, PhD Each year, the American Society of Clinical Oncology (ASCO) holds an annual meeting that shares novel breakthroughs and transformative research in oncology. [...]
GO2 for Lung Cancer is excited to announce the publication of our brand-new handbook, Navigating Small Cell Lung Cancer: 360° of HOPE. Download or order your free hard copy today. When you or someone you love is diagnosed with [...]
The American Society of Clinical Oncology (ASCO) hosts an annual meeting every spring. At this meeting, oncologists, physicians, researchers, industry members, advocacy organizations (like GO2,) patients, and caregivers come together to share and learn about the latest and most [...]
On June 13, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Augtyro (repotrectinib) for adults and children aged 12 years and older with NTRK-positive solid tumors, including non-small cell lung cancer (NSCLC). The new approval [...]
Contributing Authors: Brittney Nichols, MPH, RN-BSN, Senior Specialist, Science and Research, GO2 for Lung Cancer; Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer; and Renee Botello, MSc, Navigator, Treatment and Trials, GO2 for Lung Cancer Every [...]
On May 16, 2024, the U.S. Food and Drug Administration (FDA) granted Imdelltra (tarlatamab-dlle) accelerated approval for people with extensive stage small cell lung cancer (ES-SCLC) following progression on or after platinum-based chemotherapy. The approval is based on results [...]
Author: GO2 for Lung Cancer Specialist, Science & Research, Brittney Nichols MPH, BSN-RN Each year, scientists and doctors from across the globe gather at IASLC’s World Conference on Lung Cancer (WCLC) to discuss the latest and greatest in lung [...]